Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
23 Results for "
hyperoxaluria
" in MedChemExpress (MCE) Product Catalog:
Products (23)
23 Results for "hyperoxaluria" in MCE Product Catalog:
1
1 Cited Publications
Cat. No.: HY-W018035
CAS No.: 473-81-4
Synonyms: Glyceric Acid (20% in Water,ca.2 mol/L)
Category:
Microorganisms Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields
Target:
1
Research Areas:
Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1) .
1
Research Areas:
Nedosiran (DCR-PHXC) sodium is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran sodium represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran sodium is a GalNAc-dsRNA conjugate .
1
1 Cited Publications
Research Areas:
Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .
1
1 Cited Publications
Target:
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
N-Propargylglycine is a brain-penetrant and orally active PRODH inhibitor. N-Propargylglycine covalently modifies enzyme-bound FAD and active site lysine, causing enzyme structural distortion, protein decay, and irreversible inhibition of proline and 4-hydroxyproline catabolism. N-Propargylglycine induces UPRmt, upregulates mitochondrial chaperones and YME1L1, enhances mitochondrial proteostasis, blocks astrocytic L-proline consumption, and abolishes L-proline’s ATP-maintaining and viability-protective effects. N-Propargylglycine stimulates neural processes, increases brain proline, hydroxyproline, and sarcosine levels, partially normalizes Huntington’s disease whole brain transcriptomes. N-Propargylglycine reduces hyperoxaluria, prevents calcium oxalate stone formation, reduces kidney tubular damage, and restores weight and survival in Grhpr knockout mice. N-Propargylglycine can be used for the research of breast cancer, neurodegenerative disorders, Huntington’s disease, and primary hyperoxaluria type 2 .
1
Research Areas:
Nedosiran (DCR-PHXC) is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran is a GalNAc-dsRNA conjugate .
Cat. No.: HY-W019724
CAS No.: 563-96-2
Target:
Research Areas:
CHK-336 (Example 1) is an orally active LDHA inhibitor (IC50<1 nM). CHK-336 inhibits lactate production in mouse hepatocytes. CHK-336 can be used in the study of hyperoxaluria .
Cat. No.: HY-W088011B
CAS No.: 2836-32-0
Synonyms: Sodium hydroxyacetate, 98%
Target:
Research Areas:
D-Glyceric acid sodium is the sodium form of D-Glyceric acid (HY-139070A). D-Glyceric acid is an endogenous metabolite present in urine that can be used for the research of primary hyperoxaluria type I and glutaric acidemia type 2 .
Cat. No.: HY-113377
CAS No.: 28305-26-2
Target:
Cat. No.: HY-147064A
CAS No.: 1187-99-1
Target:
Cat. No.: HY-147064
Research Areas:
DL-4-Hydroxy-2-ketoglutarate lithium is one of the metabolites that is characteristically elevated in the urine of patients with type 3 primary hyperoxaluria (PH3), and it is produced by the accumulation of substrates of mitochondrial 4-hydroxy-2-oxoglutarate aldolase (HOGA). DL-4-Hydroxy-2-ketoglutarate lithium can be used in studies related to PH3 .
Cat. No.: HY-148610
CAS No.: 893739-96-3
Target:
Research Areas:
LDH-IN-2, a salicylic acid derivative, is an inhibitor of glycolate oxidase (GO). LDH-IN-2 decreases oxalate output in hyperoxaluric hepatocytes. LDH-IN-2 can be used for research of primary hyperoxaluria type 1 (PH1) .
Cat. No.: HY-W176012
CAS No.: 330977-65-6
Target:
Research Areas:
Glycolate oxidase-IN-1(compound 26), a salicylic acid derivative, is a glycolate oxidase (GO) inhibitor with an IC50 of 38.2 μM. Glycolate oxidase-IN-1 has the ability to reduce oxalate production in hyperoxalate hepatocytes and can be used in the study of primary hyperoxaluria type 1 (PH1) .
Cat. No.: HY-115875
CAS No.: 2776148-90-2
Target:
Research Areas:
LDHA-IN-5 is a novel, potent, dual GO/LDHA inhibitor for primary hyperoxaluria.
Cat. No.: HY-156648
CAS No.: 2408241-62-1
Target:
Research Areas:
Vamagloxistat is glycolate oxidase inhibitor, used to inhibit hyperoxaluria and kidney stones .
Target:
Cat. No.: HY-159910
Target:
Research Areas:
LH1513 is a dioxalate derivative of l-lysine (HY-N0469) that inhibits CaOx crystallization with better activity than citrate and pyruvate. LH1513 has potential preventive activity in hyperoxaluria models and effectively prevents urinary CaOx crystal formation in Agxt knockout mice. AGXT-1 is a mitochondrial protein involved in metabolism .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
